Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue
Total Revenue	$ 1,952,237	$ 5,606,914
Operating Expenses
Cost of Revenue	1,114,550	3,697,854
General and Administrative	2,491,228	2,312,505
Total Operating Expenses	3,605,778	6,010,359
Operating Losses from Operations	(1,653,541)	(403,445)
Other Income (Expense)
Interest Income	172,400	30,632
Interest Expense		(53,582)
Foreign Exchange Transaction Gain	408,095	1,462,697
Unrealized Loss on Securities Investment	(3,899,015)	(9,535,009)
Realized Loss on Securities Investment	(3,436,783)	(258,245)
Loss on Investment on Security by Equity Method	(136,380)	(24,847)
Finance Costs	(448,008)	(582,868)
Other Income	1,284,893	11,256
Total Other Expense, Net	(6,054,798)	(8,949,966)
Net Loss Income Before Income Taxes	(7,708,339)	(9,353,411)
Income Tax Expense	(222,114)	(451,337)
Net Loss	(7,930,453)	(9,804,748)
Net Loss Attributable to Non-Controlling Interest	(1,463,167)	(3,569,112)
Net Loss Attributable to Common Stockholders	(6,467,286)	(6,235,636)
Other Comprehensive Loss, Net
Unrealized Loss on Securities Investment	(9,123)	(1,987)
Foreign Currency Translation Adjustment	(649,140)	(1,769,440)
Comprehensive Loss	(8,588,716)	(11,576,175)
Comprehensive Loss Attributable to Non-controlling Interests	(1,085,395)	(4,328,924)
Comprehensive Loss Attributable to Common Stockholders	$ (7,503,321)	$ (7,247,251)
Net Loss Per Share - Basic and Diluted	$ (0.07)	$ (0.73)
Weighted Average Common Shares Outstanding - Basic and Diluted	99,184,657	8,572,222
Rental [Member]
Revenue
Total Revenue	$ 232,582
Property [Member]
Revenue
Total Revenue	1,041,524	3,894,131
Biohealth [Member]
Revenue
Total Revenue	617,471	1,712,783
Other [Member]
Revenue
Total Revenue	$ 60,660